MLLCF - Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
2024-03-15 11:20:08 ET
Molecular Partners AG (MOLN)
Q4 2023 Earnings Conference Call
March 15, 2024 08:00 AM ET
Company Participants
Seth Lewis - SVP, IR
Patrick Amstutz - CEO
Robert Hendriks - SVP, Finance
Philippe Legenne - Acting Chief Medical Officer
Anne Goubier - SVP, Research & Early Development
Daniel Steiner - SVP Research & Technology
Conference Call Participants
Richard Vosser - JPMorgan
Michael Nedelcovych - TD Cowen
Kathleen Silverman - Leerink
Joris Zimmermann - Octavian
Presentation
Operator
Good day, and welcome to the Molecular Partners Fourth Quarter and Full Year 2023 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Seth Lewis, Senior Vice President, Investor Relations. Please go ahead.
Seth Lewis
Thank you, Betsy. And welcome, everybody. Good morning and good afternoon to the 2023 full year earnings call for Molecular Partners. My name is Seth Lewis, Senior Vice President of Invest Relations. I wanted to just go over a little bit of housekeeping before we began. Obviously, we are speaking today in reference to the press release which was issued after the close of market yesterday, as well as the full year annual results which are in the annual report, which can be found on our website, molecularpartners.com. And we'll be making reference and prepared remarks today to the presentation, which slides are also available under the Investors section of our website, molecularpartners.com.
If you are following along on the presentation, we will refer you to -- we are going to make certain forward-looking statements today. And I would refer you to our latest filings and most recent filings with the SEC and with ESSEC. For the sake of the replay today, we are recording this on March 15, 2023.
If you were on Slide 3, I just wanted to take you through the agenda briefly. We are joined today by multiple members of our management team, including Patrick Amstutz, our CEO, who will take you through both the highlights of 2023 and the outlook for 2024. Robert Hendriks, our Senior Vice President of Finance, who will go over some of our financial numbers. Philippe Legenne, who is our Acting Chief Medical Officer, who will touch on our MPO533 program in AML MDS. Anne Goubier, our Senior Vice President of Research and Early Development, who will discuss the Switch-DARPin technology, as well as our c-Kit program. And Daniel Steiner, our Senior Vice President of Research and Technology, who will touch on the Radio-DARPin and platform and the DLL3 program....
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript